Investing

Orchestra BioMed Gets FDA Nod for BackBeat Study

By Dean Seal

Orchestra BioMed has gotten the go-ahead from federal regulators to start a study examining BackBeat, its atrioventricular interval modulation therapy for treating hypertension in pacemaker patients.

The biomedical company said Tuesday that the U.S. Food and Drug Administration has granted approval of an investigational device…

Read the full article here

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

Watch full video on YouTube

News

This article was written by Follow Beyond Saving is a professional in commercial real estate providing research on REITs with a focus on properties...

News

This article was written by Follow I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared...

Copyright © 2023 Repay Down. All Rights Reserved.

Exit mobile version